BrainStorm’s ALS Drug Heads to the FDA with Correction to Phase III Analyses

Submitted by admin on August 15, 2022 - 10:17am

Source:

BioSpace

News Tags:

BrainStorm Cell Therapeutics

NurOwn

ALS

FDA

clinical trials

Headline:

BrainStorm’s ALS Drug Heads to the FDA with Correction to Phase III Analyses

snippet:

BrainStorm Cell Therapeutics’ NurOwn has not traveled the smoothest path, but the amyotrophic lateral sclerosis (ALS) hopeful is now officially on its way to the FDA for review.

Search form

You are here

BrainStorm’s ALS Drug Heads to the FDA with Correction to Phase III Analyses

BrainStorm’s ALS Drug Heads to the FDA with Correction to Phase III Analyses